Bristol-Myers Squibb Co

Bristol-Myers Squibb Company is a global biopharmaceutical enterprise engaged in the discovery, development, manufacturing, and commercialization of pharmaceutical products. Its extensive portfolio of medicines targets a wide array of serious medical conditions, including those in the fields of hematology, oncology, cardiovascular health, immunology, fibrotic disorders, neuroscience, and COVID-19. The company's prominent therapies include Revlimid, an oral immunomodulator prescribed for multiple myeloma; Eliquis, an oral inhibitor used to lower the risk of stroke/systemic embolism in non-valvular atrial fibrillation and to treat deep vein thrombosis/pulmonary embolism; and Opdivo, a key anti-cancer agent. Additional significant products are Pomalyst/Imnovid for multiple myeloma; Orencia, which addresses active rheumatoid arthritis and psoriatic arthritis; and Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia. Its lineup further features Yervoy for unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy; Reblozyl for adult patients experiencing anemia due to beta thalassemia; and Empliciti, also for multiple myeloma. Recent innovations include Zeposia for relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for specific types of B-cell lymphoma; Inrebic, an oral kinase inhibitor for myelofibrosis; and Onureg for adult patients with acute myeloid leukemia. Bristol-Myers Squibb distributes its pharmaceutical offerings to a broad network of customers, encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and various government agencies. The organization, established in 1887 and previously known as Bristol-Myers Company, is headquartered in New York, New York.